Pharma M&A deal value surges by 101% QoQ in Q1 2025 despite US political turbulence
Mergers and acquisitions (M&As) in the biopharmaceutical industry surged 101% in total deal value in the first quarter (Q1) of…
Mergers and acquisitions (M&As) in the biopharmaceutical industry surged 101% in total deal value in the first quarter (Q1) of…
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), once focused on treating diabetes and obesity, are now emerging as potential treatments for a…
The post-traumatic stress disorder (PTSD) market is expected to grow at a high compound annual growth rate of 16.1% from…
Biopharmaceutical drug company venture financing witnessed a downturn in Q1 2025, with $6.5bn raised—a 20.2% decline from the $8.1bn raised…
In early 2025, US President Donald Trump mentioned the possibility of potential tariffs on foreign-made pharmaceuticals. This threat was raised…
While the pharmaceutical industry is currently exempt from US tariffs, there is an increased risk to the stability of the…
The top 20 biopharmaceutical companies demonstrated a strong start to 2025, despite ongoing uncertainty surrounding the potential impact of President…
Atopic dermatitis (AD) is a widespread, chronic inflammatory skin condition that can affect patients of all ages and is the…
Chimeric antigen receptor (CAR) T-cell therapies have drastically changed treatment paradigms in relapsed and refractory (R/R) haematological malignancies since the…
At the 35th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Vienna, Austria, the development of…